CClinicalTrials.gg
CompletedNCT00559572Updated Jan 16, 2013

Effects of Motivating People With Schizophrenia to Exercise

An interventional study of Motivational group sessions and Time and attention control group sessions in Schizophrenia, sponsored by The University of Tennessee, Knoxville. Completed at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2013-01-16.

Sponsored by The University of Tennessee, Knoxville · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
22 Years and older
Sex
All
01

Study summary

This study will evaluate the impact of motivational guidance to exercise on people with schizophrenia, based on their participation in a walking program.

Read the detailed description

Schizophrenia is a chronic brain disorder that affects about 1% of Americans. People with schizophrenia experience extreme paranoia, often claiming that they hear voices not heard by others and that others are invading or controlling their minds with the intent to hurt them. More specific symptoms include hallucinations, delusional behaviors, disordered movements, and decreased ability to comprehend and apply information to everyday activities. The severity of these symptoms makes self-care and regular exercise difficult for people with schizophrenia. The fatality rate from diabetes, heart disease, and other obesity-related illnesses is significantly higher in people with schizophrenia. Exercise is known to reduce health problems associated with obesity, yet few studies have encouraged exercise as a treatment method for improving the health of those with schizophrenia. Furthermore, the long-term physical and mental effects of consistent exercise on people with schizophrenia are not well-known. This study will evaluate the impact of motivational guidance to exercise on people with schizophrenia, based on their attendance, persistence, and compliance to a walking program.

Participants in this study will be randomly assigned to one of two groups. Both groups will continue their regular medications and treatments throughout the study. Upon entry, members of both groups will complete the same two forms concerning attitudes toward exercise. Group 1 participants will attend weekly 1-hour exercise information sessions for 4 weeks. Group 2 participants will attend weekly 1-hour general health information sessions for the same 4 weeks. Participants of both groups will then take part in identical 16-week walking programs. The walking program will consist of three 30- to 50-minute walks per week, including 10 minutes of warm up and 10 minutes of cool down stretching. All participants will gradually increase their walking time from 5 minutes to 30 minutes during the program. At the completion of the walking programs, participants of both groups will complete repeat forms about their attitudes toward exercise. There will be no follow-up visits for the participants.

02

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Exercise
  • Group Counseling
  • Obesity
03

In context

Schizophrenia

3,471 studies on the registry are indexed under Schizophrenia; 472 are open to participants now.

This study's enrollment of 80 is above the median of 70 across 2,872 interventional studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

The University of Tennessee, Knoxville is the lead sponsor of 95 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Meets DSM-IV criteria for schizophrenia
  • Speaks English
  • Stable medication regimen
  • Able to receive medical clearance for moderate exercise

Exclusion criteria

Exclusion Criteria:

  • Hospitalized within 1 year of study entry for angina, heart attack, or cardiac surgery
  • Diagnosed with congestive heart failure
  • Has a pacemaker
  • Heart rate less than 50 bpm or more than 100 bpm at rest
  • Uncontrolled hypertension
  • History of spinal or hip fracture
  • Unable to walk or move around without assistance
  • Any other medical condition, in the opinion of primary care provider, that would prevent safe participation in the study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    1

    Exercise information group

    Behavioral: Motivational group sessions

  • Active comparator
    2

    General health information group

    Other: Time and attention control group sessions

Interventions

  • BehavioralMotivational group sessions

    Motivational group sessions include 4 weeks of weekly 1-hour exercise information sessions.

  • OtherTime and attention control group sessions

    Time and attention control group sessions include 4 weeks of weekly 1-hour general health information sessions.

06

What researchers measure

Primary outcomes

  1. Exercise group attendance

    Time frame: Measured at Week 16

  2. Exercise group persistence

    Time frame: Measured at Weeks 4,8, 12 & 16

  3. Exercise group compliance

    Time frame: Measured at Weeks 4,8,12 & 16

  4. Exercise attitude

    Time frame: Measured at Weeks 4,8,12 and 16

07

Study locations

1 site
  • Helen Ross McNabb Center
    Knoxville, Tennessee 37917, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 16, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00559572
Lead sponsor
The University of Tennessee, Knoxville
Collaborators
National Institute of Mental Health (NIMH)
Responsible party
Brenda Lawson (Compliance Officer, IRB Administrator, The University of Tennessee, Knoxville) — Principal investigator
First posted
Nov 16, 2007
Start date
Nov 2007
Primary completion
Aug 2009
Completion
Aug 2009
Last update
Jan 16, 2013

Study contacts

Lora L. Beebe, PhD, PMHNP, BC
principal investigator · University of Tennessee

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion